TNP-470 (AGM-1470): Mechanisms of action and early clinical development
- 31 December 1996
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 32 (14), 2520-2527
- https://doi.org/10.1016/s0959-8049(96)00388-7
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Clinical Applications of Research on AngiogenesisThe New England Journal of Medicine, 1995
- Suppression of Cyclin D1 mRNA Expression by the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1994
- Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)British Journal of Cancer, 1994
- Angiogenesis.Journal of Biological Chemistry, 1992
- Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parentBiochemical and Biophysical Research Communications, 1991
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990
- Anti-AngiogenesisAnnals of Surgery, 1972
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISThe Journal of Experimental Medicine, 1971
- Fumagillin (H-3), a New Antibiotic with Amebicidal PropertiesScience, 1951